There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Many of you may remember from this column that I have multiple myeloma, or cancer of the bone marrow. In January, I will be headed to UVA hospital for a ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ...

Angela Zarybnicky, 55, of Pine Island, FL passed away November 4, 2024 from multiple myeloma. She was a registered nurse and ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...